ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

41.80
0.399999
( 0.97% )
Updated: 05:22:10
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
41.80
Bid
41.40
Ask
42.20
Volume
251
41.80 Day's Range 41.80
21.40 52 Week Range 58.50
Previous Close
41.40
Open
41.80
Last Trade Time
03:30:34
Average Volume (3m)
150
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.800001-8.3333355263245.645.639.650741.91558185DE
4-6.400001-13.278010373448.248.239.617842.85404101DE
12-3.400001-7.5221261061945.251.539.615046.14471602DE
26-7.200001-14.69387959184957.539.616948.03577184DE
5219.79999989.99999545452258.521.39999917944.24911102DE
15617.99999975.630247899223.858.51917141.97393714DE
26017.99999975.630247899223.858.51917141.97393714DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CXFChimerix Inc
1.758 €
(115.97%)
133.54k
1TGTriton Minerals Ltd
0.006 €
(33.33%)
50.04k
0IU0Us Critical Metals Corp
0.07 €
(25.45%)
2.86k
DJDADieteren Group
161.00 €
(24.81%)
1.72k
LL3PanGenomic Health Inc
0.1514 €
(24.40%)
1.87k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
560
3RITurmalina Metals Corp
0.0102 €
(-53.21%)
300
PA8Paion AG
0.0132 €
(-45.90%)
784
UH7ATennant Minerals NL
0.0055 €
(-26.67%)
20k
N790Blackbird Critical Metals Corp
0.0115 €
(-25.81%)
4k
AXIAtos SE
0.0024 €
(-11.11%)
312.25M
D7GNel ASA
0.271 €
(0.41%)
1.71M
PF8European Lithium Limited
0.0256 €
(-4.48%)
1.61M
3CPXiaomi Corporation
3.8255 €
(-1.78%)
1.17M
24YBrainchip Holdings Ltd
0.1552 €
(12.63%)
636.87k

Discussion

View Full Feed
rickstereo3333 rickstereo3333 4 minutes ago
Once again for the dolt who loves green....based on the wording that you cant read, nowhere did the report state that the additional 2 months had anything to do with submitting IDE.....as per usual you arseclowns just assumed it did.

As Vivos stated, their NEW sterility process will b
RDGL
Iggy_Bot Iggy_Bot 4 minutes ago
Long overdue.
JamesF1 JamesF1 5 minutes ago
Methotrexate tablets are available from multiple manufacturers. The FDA shortage page does not list Elite’s product at all. It’s not a needle mover, but it should be on the FDA list.
ELTP
JJZander JJZander 7 minutes ago
Pink current 
ABVN
glenn1919 glenn1919 7 minutes ago
GELS......CPIX.....JTAI......RVPH.......https://stockcharts.com/h-sc/ui?s=RVPH&p=D&yr=0&mn=2&dy=12&id=p84071410134
CPIX JTAI RVPH
Stino2 Stino2 8 minutes ago
the question is when is the company coming out with news???
CIVX
Nelson2 Nelson2 10 minutes ago
Well boyz. We are poised for the $3+ next week. The greed in me says $4+

GLTA
BB
TheKid5 TheKid5 10 minutes ago
Newsday, Tuesday, Today, Hooray👀🙃
CLNV
Sweetleaf Sweetleaf 11 minutes ago
Uh oh... new price target by some nobody analyst ... company must want to sell some shares.. so funny so obvious. These thinly traded non trusted companies need to try anything they can to sell shares. They will finally give up and the price will plummet to where it belongs...under .50 where t
RNXT
Bull_Dolphin Bull_Dolphin 12 minutes ago
It's a good day to not be a Desi:

https://slaynews.com/news/calls-grow-bill-gates-arrest-admits-using-india-kind-laboratory-test-vaccines/
RealDutch RealDutch 12 minutes ago
LoL. Make a poster of it and hang it above your bed.
ITUP
glenn1919 glenn1919 13 minutes ago
NRDY............................https://stockcharts.com/h-sc/ui?s=NRDY&p=W&b=5&g=0&id=p86431144783
NRDY
nowwhat2 nowwhat2 14 minutes ago
So tell us then.......How ( or why ) did clearing my advfn/ihub cache, instantly solve the glitch I was experiencing ?
Bull_Dolphin Bull_Dolphin 14 minutes ago
And here's another travesty that needs to be unwound:

https://alphanews.org/derek-chauvin-hires-new-attorney-plans-to-ask-for-convictions-to-be-overturned/
glenn1919 glenn1919 15 minutes ago
NBTX...........................https://stockcharts.com/h-sc/ui?s=NBTX&p=W&b=5&g=0&id=p86431144783
NBTX
bluebird50 bluebird50 15 minutes ago
Link?? TIA
HMBL
Chiron Chiron 16 minutes ago
The buzz on X about $RDAR is astounding! Ground swell coming, when this goes PC and updates start flowing it’s going to get crazy in here
RDAR
Bull_Dolphin Bull_Dolphin 17 minutes ago
How does that saying go, "Justice delayed is justice denied."
Sydney Powell, taken out of the game for years, finally gets cleared:

https://x.com/Real_RobN/status/1865845929699684739

Love this quote from testimony within:

“You have to be a damn
glenn1919 glenn1919 18 minutes ago
RVPH...........................https://stockcharts.com/h-sc/ui?s=RVPH&p=W&b=5&g=0&id=p86431144783
RVPH
Mark954 Mark954 18 minutes ago
Oh Wow!  Things just got a hell of a lot more interesting, didn't it ! !

Mark out 
TCRI
Jake731 Jake731 20 minutes ago
GOOD MORNING ALL.






TPTW……!!!!!!!
TPTW
glenn1919 glenn1919 21 minutes ago
CRDF........................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783
CRDF
sab63090 sab63090 21 minutes ago
Some of you certainly heard about Prof. Robert Shiller (Yale) who predicted the Crash of 2008 and nobody believed it! He now is saying the high home prices are next. I might be wrong, but I remember quite some years ago that I attended a fancy function at Club 21 in NYC (now closed during the pand
AVXL
lovethatgreen lovethatgreen 21 minutes ago
Rof
You don't know the answer to that but you clamoring on about parallel this and parallel that is entertaining
Like you fancying yourself as knowing anything is comical Af
RDGL
Chiron Chiron 22 minutes ago
$RDAR will see .01+ folks, you are early in the game.
RDAR

Your Recent History

Delayed Upgrade Clock